Condition 1: Mental and behavioural disorders. Condition 2: Mental and behavioural disorders. Condition 3: Mental and behavioural disorders. Condition 4: Mental and behavioural disorders. Condition 5: Mental and behavioural disorders. Condition 6: Mental and behavioural disorders. Schizophrenia, schizotypal and delusional disorders Mood [affective] disorders Neurotic, stress-related and somatoform disorders F60-F61-F62-F63-F64-F65-FF66-F67-F68-F69 F60-F61-F62-F63-F64-F65-FF66-F67-F68-F69 U
Conditions
Interventions
Intervention 1: cap memantine first day 5 mg capsule twice a day and the second day, three times a day, then 10 mg capsule twice a day (morning and night) until the end of ECT treatment. Intervention
Treatment - Drugs
cap memantine first day 5 mg capsule twice a day and the second day, three times a day, then 10 mg capsule twice a day (morning and night) until the end of ECT treatment
Placebo capsules, starch capsules 5 mg in the morning and evening of the first day, second day morning noon and night and then 10 mg capsules morning and night until the end of ECT treatment
Sponsors
Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: This study was done on patients in Sanandaj in 1392 in Qods hospital admissions and physician elected to receive ECT. Inclusion criteria: Patients between 60-18 years of age who are candidates for ECT; Patient or legal guardian to sign an informed consent form; Number of ECT sessions is between 4 to 12 sessions; Location is the city of Sanandaj. Exclusion criteria: Abuse or dependence on alcohol and drugs during the 3 months prior to admission (excluding nicotine or caffeine); Proven kidney disease (Renal Failure proven); Epilepsy; Mental Retardation based on clinical evaluation Resident Project; Delirium, Dementia and Cognitive disorders; Pregnancy and lactation; Use of Memantine than 3 months prior to admission; Patients who are receiving Thiazide diuretics; History of allergic symptoms and side effect with Memantine.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function. Timepoint: ECT prior to and after completion of the. Method of measurement: MMSE and Digit Span Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of the sizure. Timepoint: During ECT sessions. Method of measurement: View and review patient records.;Delayed onset sizure. Timepoint: Electric convulsive therapy during hospital stay. Method of measurement: patients visit and file check. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzad Maroufi
Kurdistan University of Medical Sciences
Outcome results
None listed